Artelo Biosciences (NASDAQ:ARTL) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Artelo Biosciences (NASDAQ:ARTL) from a strong sell rating to a sell rating in a report issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Artelo Biosciences in a research note on Friday, March 27th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Artelo Biosciences presently has an average rating of “Reduce” and an average target price of $54.00.

Artelo Biosciences Stock Performance

Shares of NASDAQ ARTL opened at $1.84 on Friday. The stock has a fifty day moving average price of $4.88 and a two-hundred day moving average price of $5.03. The firm has a market cap of $1.73 million, a P/E ratio of -0.03 and a beta of 0.05. Artelo Biosciences has a 1 year low of $1.77 and a 1 year high of $85.80.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($4.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($3.22).

About Artelo Biosciences

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.